^
    9d
    Momelotinib Effectiveness in Myelofibrosis (clinicaltrials.gov)
    P=N/A, N=93, Not yet recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto
    New trial • Real-world evidence
    |
    Ojjaara (momelotinib)
    13d
    Development of potent JAK1/2 PROTAC degraders for the treatment of inflammatory bowel diseases. (PubMed, Eur J Med Chem)
    Herein, a novel series of PROTAC degraders based on momelotinib were designed and synthesised...Furthermore, in vivo studies demonstrated that A8 significantly reduced inflammatory responses and colon injury by suppressing the JAK/STAT3 signalling pathway. Overall, A8 represents a novel JAK1/2 degrader as a lead compound for IBD for the first time, which deserves further development.
    Journal
    |
    JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • CRBN (Cereblon) • JAK1 (Janus Kinase 1)
    |
    Ojjaara (momelotinib)
    1m
    Advancements in myelofibrosis management: a comprehensive analysis of Ojjaara (Momelotinib) therapy and clinical perspectives. (PubMed, Ann Med Surg (Lond))
    This review examines the role of momelotinib in treating MF, focusing on its mechanism, clinical benefits, patient selection criteria, monitoring strategies, potential side effects, and findings from key clinical trials. While promising, careful patient management is essential to minimize adverse effects and optimize the therapeutic benefits of momelotinib in MF treatment.
    Review • Journal
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1)
    |
    Ojjaara (momelotinib)
    2ms
    Population Pharmacokinetics and Exposure-Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis. (PubMed, Clin Pharmacol Ther)
    Greater TAM exposure was significantly associated with lower odds of grade 3/4 anemia and higher odds of any-grade peripheral neuropathy, although the latter was infrequently observed in phase III trials. There was no significant relationship with grade ≥ 3 thrombocytopenia or any-grade diarrhea.
    PK/PD data • Journal
    |
    JAK2 (Janus kinase 2) • ACVR1 (Activin A Receptor Type 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Ojjaara (momelotinib)
    3ms
    Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study. (PubMed, Eur J Haematol)
    The safety profile was similar to that reported in clinical trials, with most toxicities of grade I-II. In conclusion, our real-life results support the use of momelotinib as an effective and safe therapeutic option for heavily pre-treated, cytopenic MF patients in real-world clinical practice.
    Clinical • Journal
    |
    ACVR1 (Activin A Receptor Type 1)
    |
    Ojjaara (momelotinib)
    3ms
    Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes. (PubMed, J Hematol)
    Nearly 50% of PMF patients experience anemia (hemoglobin (Hb) < 10 g/dL), often worsened by JAK inhibitors like ruxolitinib and fedratinib. However, heterogeneity in control groups limited direct efficacy comparisons. Larger studies are needed to confirm its effectiveness and safety.
    Retrospective data • Journal
    |
    JAK1 (Janus Kinase 1) • ACVR1 (Activin A Receptor Type 1) • CALR (Calreticulin) • MPL (MPL Proto-Oncogene, Thrombopoietin Receptor)
    |
    Jakafi (ruxolitinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)
    4ms
    A new era in the treatment of myeloproliferative neoplasms (PubMed, Rinsho Ketsueki)
    In PV, ropeginterferon alfa-2b has shown potential disease-modifying effects by reducing the JAK2 V617F allele burden. For ET, treatment remains focused on thrombosis prevention, with hydroxyurea as the mainstay, and novel agents such as pegylated interferon and bomedemstat (LSD1 inhibitor) are also under development. In MF, the evolution of JAK inhibitors is particularly noteworthy, with momelotinib and pacritinib showing potential benefits in alleviating anemia. Additionally, now that HemeSight® is covered by Japanese national health insurance, genetic mutation analysis has become more accessible, paving the way for risk classification based on genetic profiling. This review provides a comprehensive update on the latest risk stratification and therapeutic strategies for MPNs, highlighting emerging treatments and their potential impact on disease management.
    Review • Journal
    |
    JAK2 (Janus kinase 2)
    |
    Vonjo (pacritinib) • hydroxyurea • Ojjaara (momelotinib) • bomedemstat (MK-3543) • Besremi (ropeginterferon alfa-2b-njft)
    4ms
    Momelotinib During and After HCT in Myelofibrosis (clinicaltrials.gov)
    P1, N=28, Not yet recruiting, Massachusetts General Hospital
    New P1 trial
    |
    Ojjaara (momelotinib)
    4ms
    Momelotinib in VEXAS Syndrome (clinicaltrials.gov)
    P2, N=57, Not yet recruiting, Groupe Francophone des Myelodysplasies
    New P2 trial
    |
    Ojjaara (momelotinib)
    5ms
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P1 trial
    |
    azacitidine • decitabine • Ojjaara (momelotinib)
    5ms
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=80, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ojjaara (momelotinib)
    7ms
    ODYSSEY: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (clinicaltrials.gov)
    P2, N=56, Recruiting, GlaxoSmithKline | Phase classification: P1/2 --> P2
    Phase classification
    |
    Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib)